290 related articles for article (PubMed ID: 33894103)
1. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
Lapumnuaypol K; Pisarcik D; Putthapiban P; Sukhumthammarat W; Wijarnpreecha K; Thongprayoon C; Ungprasert P
Indian J Med Res; 2020 Dec; 152(6):562-567. PubMed ID: 34145095
[TBL] [Abstract][Full Text] [Related]
3. Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.
Benetti F; de Araújo A; de Maman Júnior I; Coelho Borges Cheinquer C; Herz Wolff F; Cheinquer H
Arch Endocrinol Metab; 2024 May; 68():e220480. PubMed ID: 38709148
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Hussein HA; Allam AS; Moaty ASA
Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
[TBL] [Abstract][Full Text] [Related]
5. Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8
Perpiñán E; Pérez-Del-Pulgar S; Londoño MC; Mariño Z; Lens S; Leonel T; Bartres C; García-López M; Rodriguez-Tajes S; Forns X; Koutsoudakis G
J Viral Hepat; 2020 Dec; 27(12):1408-1418. PubMed ID: 32812325
[TBL] [Abstract][Full Text] [Related]
6. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
8. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
[TBL] [Abstract][Full Text] [Related]
9. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience.
Dalbeni A; Villani R; Bevilacqua M; Sacco F; Faccincani D; Cattazzo F; Cavallone F; Mantovani A; Ceruti V; Ieluzzi D; Paon V; Mantovani A; Serviddio G; Sacerdoti D
J Dig Dis; 2022 May; 23(5-6):324-330. PubMed ID: 35700113
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents.
Ciancio A; Ribaldone DG; Dotta A; Giordanino C; Sacco M; Fagoonee S; Pellicano R; Saracco GM
Liver Int; 2021 Feb; 41(2):276-287. PubMed ID: 32998174
[TBL] [Abstract][Full Text] [Related]
12. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes.
Jang TY; Lin YH; Liang PC; Yeh ML; Huang CI; Liu TW; Wei YJ; Hsu PY; Yang JF; Hou NJ; Wang CW; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2022 Sep; 38(9):897-906. PubMed ID: 35670210
[TBL] [Abstract][Full Text] [Related]
14. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C.
Weidner P; Boettche D; Zimmerer T; Burgermeister E; Teufel A; Ebert MPA; Antoni C
J Gastrointestin Liver Dis; 2018 Sep; 27(3):281-289. PubMed ID: 30240472
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
16. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
[TBL] [Abstract][Full Text] [Related]
17. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control.
Andres J; Barros M; Arutunian M; Zhao H
J Manag Care Spec Pharm; 2020 Jun; 26(6):775-781. PubMed ID: 32463777
[TBL] [Abstract][Full Text] [Related]
19. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.
Ciancio A; Bosio R; Bo S; Pellegrini M; Sacco M; Vogliotti E; Fassio G; Bianco Mauthe Degerfeld AGF; Gallo M; Giordanino C; Terzi di Bergamo L; Ribaldone D; Bugianesi E; Smedile A; Rizzetto M; Saracco GM
J Med Virol; 2018 Feb; 90(2):320-327. PubMed ID: 28960353
[TBL] [Abstract][Full Text] [Related]
20. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
